SS-31 (Elamipretide)

FDA-approved product existsMitochondrial ResearchRecovery & tissue repairWeight & metabolicLongevity & cellular
6.0

Worth trying, BioHarmony verdict

BioHarmony score 6.0 out of 10

SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide that binds cardiolipin. Karaa 2023 found no broad PMM benefit in MMPOWER-3, while FDA granted accelerated Forzinity approval for Barth syndrome in patients weighing at least 30 kg.

Read full report

What is SS-31 (Elamipretide)?

SS-31, now known clinically as elamipretide and marketed as Forzinity for Barth syndrome, is a mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane. Cardiolipin helps organize mitochondrial cristae, the folds where electron transport chain complexes sit and ATP is produced. Birk 2013 showed SS-31 interacting with cardiolipin in ischemic mitochondria, while Szeto 2014 framed the compound as the lead cardiolipin-protective peptide in the Szeto-Schiller class.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

How it is thought to work

Binds cardiolipin on the inner mitochondrial membrane, supports cristae architecture and electron transport chain supercomplex organization, and reduces mitochondrial ROS leak.

Safety watch-outs

  • Injection-site infection
  • New severe weakness or muscle pain

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelFORZINITY prescribing information for Barth syndrome
PopulationPatients weighing at least 30 kg with Barth syndrome
Dose40 mg
RouteSubcutaneous injection
FrequencyOnce daily
DurationAs directed in the approved prescribing information
PreparationReady-to-use 80 mg/mL solution in a multi-dose vial; no reconstitution. The label directs discarding an opened vial after 8 days.
Source: Dosage and Administration sections 2.2-2.4; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (6)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingApproved product exists; compounded copies are not FDA approved

FDA approved elamipretide as Forzinity in 2025 for improving muscle strength in adults and pediatric patients with Barth syndrome who weigh at least 30 kg.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.